Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
DoorDash, Inc. stock logo
DASH
DoorDash
$167.97
+1.1%
$166.80
$143.30
$285.50
$72.97B1.874.81 million shs8.95 million shs
Kimberly-Clark Corporation stock logo
KMB
Kimberly-Clark
$99.19
+2.0%
$99.82
$92.42
$144.30
$32.93B0.295.52 million shs3.87 million shs
Kenvue Inc. stock logo
KVUE
Kenvue
$17.69
+1.8%
$17.67
$14.02
$25.17
$33.97B0.5534.42 million shs23.92 million shs
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
$86.26
+4.3%
$84.42
$28.06
$103.00
$7.10B2.06697,633 shs426,842 shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
DoorDash, Inc. stock logo
DASH
DoorDash
-5.51%-3.39%+6.19%-15.16%-19.11%
Kimberly-Clark Corporation stock logo
KMB
Kimberly-Clark
-0.48%-1.26%+1.11%-5.82%-25.76%
Kenvue Inc. stock logo
KVUE
Kenvue
-0.19%-0.85%+1.41%-3.25%-26.34%
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
+2.48%-1.36%-3.15%+6.45%+146.31%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
DoorDash, Inc. stock logo
DASH
DoorDash
$167.97
+1.1%
$166.80
$143.30
$285.50
$72.97B1.874.81 million shs8.95 million shs
Kimberly-Clark Corporation stock logo
KMB
Kimberly-Clark
$99.19
+2.0%
$99.82
$92.42
$144.30
$32.93B0.295.52 million shs3.87 million shs
Kenvue Inc. stock logo
KVUE
Kenvue
$17.69
+1.8%
$17.67
$14.02
$25.17
$33.97B0.5534.42 million shs23.92 million shs
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
$86.26
+4.3%
$84.42
$28.06
$103.00
$7.10B2.06697,633 shs426,842 shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
DoorDash, Inc. stock logo
DASH
DoorDash
-5.51%-3.39%+6.19%-15.16%-19.11%
Kimberly-Clark Corporation stock logo
KMB
Kimberly-Clark
-0.48%-1.26%+1.11%-5.82%-25.76%
Kenvue Inc. stock logo
KVUE
Kenvue
-0.19%-0.85%+1.41%-3.25%-26.34%
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
+2.48%-1.36%-3.15%+6.45%+146.31%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
DoorDash, Inc. stock logo
DASH
DoorDash
2.78
Moderate Buy$259.3154.38% Upside
Kimberly-Clark Corporation stock logo
KMB
Kimberly-Clark
2.19
Hold$114.9315.87% Upside
Kenvue Inc. stock logo
KVUE
Kenvue
2.19
Hold$19.339.28% Upside
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
2.96
Moderate Buy$118.1036.91% Upside

Current Analyst Ratings Breakdown

Latest DASH, KVUE, KMB, and KYMR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/6/2026
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
Initiated CoverageBuy$106.00
5/1/2026
DoorDash, Inc. stock logo
DASH
DoorDash
Lower Price TargetNeutral$240.00 ➝ $206.00
4/30/2026
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
Reiterated RatingOverweight$119.00
4/29/2026
DoorDash, Inc. stock logo
DASH
DoorDash
DowngradeHold (C)Hold (C-)
4/29/2026
Kimberly-Clark Corporation stock logo
KMB
Kimberly-Clark
Boost Price TargetNeutral$105.00 ➝ $106.00
4/27/2026
DoorDash, Inc. stock logo
DASH
DoorDash
Initiated CoverageBuy$225.00
4/27/2026
DoorDash, Inc. stock logo
DASH
DoorDash
UpgradeStrong-Buy$225.00
4/21/2026
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
Reiterated RatingSell (D-)
4/15/2026
DoorDash, Inc. stock logo
DASH
DoorDash
Set Price Target$276.00
4/15/2026
Kenvue Inc. stock logo
KVUE
Kenvue
Lower Price TargetNeutral$20.00 ➝ $19.00
4/14/2026
Kimberly-Clark Corporation stock logo
KMB
Kimberly-Clark
Lower Price TargetEqual Weight$105.00 ➝ $99.00
(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
DoorDash, Inc. stock logo
DASH
DoorDash
$13.72B5.32$3.94 per share42.60$23.10 per share7.27
Kimberly-Clark Corporation stock logo
KMB
Kimberly-Clark
$16.45B2.00$10.35 per share9.58$5.77 per share17.19
Kenvue Inc. stock logo
KVUE
Kenvue
$15.12B2.25$1.42 per share12.43$5.62 per share3.15
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
$39.21M180.97N/AN/A$18.72 per share4.61
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
DoorDash, Inc. stock logo
DASH
DoorDash
$935M$2.1279.2336.59N/A6.82%10.15%5.49%5/6/2026 (Confirmed)
Kimberly-Clark Corporation stock logo
KMB
Kimberly-Clark
$2.02B$6.3715.5713.444.5812.80%152.79%14.43%N/A
Kenvue Inc. stock logo
KVUE
Kenvue
$1.47B$0.7722.9815.253.899.72%19.72%7.72%5/7/2026 (Confirmed)
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
-$311.35M-$3.57N/AN/AN/A-611.94%-24.71%-22.05%N/A

Latest DASH, KVUE, KMB, and KYMR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2026Q1 2026
Kenvue Inc. stock logo
KVUE
Kenvue
$0.27N/AN/AN/A$3.84 billionN/A
5/6/2026Q1 2026
DoorDash, Inc. stock logo
DASH
DoorDash
$0.39$0.42+$0.03$0.42$4.15 billion$4.04 billion
4/30/2026Q1 2026
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
-$0.89-$0.71+$0.18-$0.71$8.27 million$34.37 million
4/28/2026Q1 2026 Prepared Remarks
Kimberly-Clark Corporation stock logo
KMB
Kimberly-Clark
$1.93$1.97+$0.04$2.00$4.09 billion$4.16 billion
2/26/2026Q4 2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
-$0.77-$0.97-$0.20-$0.97$14.80 million$2.87 million
2/18/2026Q4 2025
DoorDash, Inc. stock logo
DASH
DoorDash
$0.58$0.48-$0.10$0.48$3.98 billion$3.96 billion
2/17/2026Q4 2025
Kenvue Inc. stock logo
KVUE
Kenvue
$0.22$0.27+$0.05$0.17$3.68 billion$3.78 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
DoorDash, Inc. stock logo
DASH
DoorDash
N/AN/AN/AN/AN/A
Kimberly-Clark Corporation stock logo
KMB
Kimberly-Clark
$5.125.16%+3.32%80.38%54 Years
Kenvue Inc. stock logo
KVUE
Kenvue
$0.834.69%N/A107.79%1 Years
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
N/AN/AN/AN/AN/A

Latest DASH, KVUE, KMB, and KYMR Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/29/2026
Kenvue Inc. stock logo
KVUE
Kenvue
quarterly$0.20754.82%5/13/20265/13/20265/27/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
DoorDash, Inc. stock logo
DASH
DoorDash
0.27
1.41
1.41
Kimberly-Clark Corporation stock logo
KMB
Kimberly-Clark
3.38
0.77
0.55
Kenvue Inc. stock logo
KVUE
Kenvue
0.66
0.96
0.68
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
N/A
10.81
10.81

Institutional Ownership

CompanyInstitutional Ownership
DoorDash, Inc. stock logo
DASH
DoorDash
90.64%
Kimberly-Clark Corporation stock logo
KMB
Kimberly-Clark
76.29%
Kenvue Inc. stock logo
KVUE
Kenvue
97.64%
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
DoorDash, Inc. stock logo
DASH
DoorDash
5.83%
Kimberly-Clark Corporation stock logo
KMB
Kimberly-Clark
0.75%
Kenvue Inc. stock logo
KVUE
Kenvue
1.59%
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
16.01%
CompanyEmployeesShares OutstandingFree FloatOptionable
DoorDash, Inc. stock logo
DASH
DoorDash
31,400434.43 million409.10 millionOptionable
Kimberly-Clark Corporation stock logo
KMB
Kimberly-Clark
36,000331.94 million329.45 millionOptionable
Kenvue Inc. stock logo
KVUE
Kenvue
22,0001.92 billion1.89 billionOptionable
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
17082.26 million69.09 millionOptionable

Recent News About These Companies

Equities Analysts Issue Forecasts for KYMR Q2 Earnings
Kymera Therapeutics (NASDAQ:KYMR) Upgraded at Wall Street Zen
Kymera Therapeutics Q1 Earnings Call Highlights

New MarketBeat Followers Over Time

Media Sentiment Over Time

DoorDash stock logo

DoorDash NASDAQ:DASH

$167.97 +1.83 (+1.10%)
Closing price 04:00 PM Eastern
Extended Trading
$185.45 +17.48 (+10.41%)
As of 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

DoorDash, Inc., together with its subsidiaries, operates a commerce platform that connects merchants, consumers, and independent contractors in the United States and internationally. The company operates DoorDash Marketplace and Wolt Marketplace, which provide various services, such as customer acquisition, demand generation, order fulfillment, merchandising, payment processing, and customer support. It also offers membership products, including DashPass and Wolt+; DoorDash Drive and Wolt Drive, which are white-label delivery fulfillment services that enable merchants that have generated consumer demand through their channels to fulfill demand using its platform; DoorDash Storefront that enables merchants to offer consumers on-demand access to e-commerce; and Bbot, which offers merchants digital ordering and payment solutions for in-store and online channels. In addition, the company enables merchants to advertise and promote on its platform to acquire consumers. The company was formerly known as Palo Alto Delivery Inc. and changed its name to DoorDash, Inc. in 2015. DoorDash, Inc. was founded in 2013 and is headquartered in San Francisco, California.

Kimberly-Clark stock logo

Kimberly-Clark NASDAQ:KMB

$99.19 +1.99 (+2.05%)
Closing price 04:00 PM Eastern
Extended Trading
$99.51 +0.32 (+0.32%)
As of 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care and consumer tissue products in the United States. It operates through three segments: Personal Care, Consumer Tissue, and K-C Professional. The company's Personal Care segment offers disposable diapers, training and youth pants, swimpants, baby wipes, feminine and incontinence care products, reusable underwear, and other related products under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Sweety, Kotex, U by Kotex, Intimus, Thinx, Poise, Depend, Plenitud, Softex, and other brand names. Its Consumer Tissue segment provides facial and bathroom tissues, paper towels, napkins, and related products under the Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, Neve, and other brand names. The company's K-C Professional segment offers wipers, tissues, towels, apparel, personal protective equipment, soaps, and sanitizers under the Kleenex, Scott, WypAll, Kimtech, and KleenGuard brands. It also sells household use products directly to supermarkets, mass merchandisers, drugstores, warehouse clubs, variety and department stores, and other retail outlets, as well as through other distributors and e-commerce; and away-from-home use products directly to distributors, manufacturing, lodging, office building, food service, and public facilities, as well as through e-commerce. Kimberly-Clark Corporation was founded in 1872 and is headquartered in Dallas, Texas.

Kenvue stock logo

Kenvue NYSE:KVUE

$17.69 +0.32 (+1.85%)
Closing price 03:59 PM Eastern
Extended Trading
$17.61 -0.08 (-0.44%)
As of 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Kenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands. The Skin Health and Beauty segment provides face and body care, hair, sun, and other care products under the Neutrogena, Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Rogaine, and OGX brand names. The Essential Health segment offers oral and baby, women's health, wound, and other care products under the Listerine, Johnson's, Band-Aid, and Stayfree, o.b., tampons, Carefree, and Desitin Diaper Rash brands. The company was incorporated in 2022 and is headquartered in Skillman, New Jersey.

Kymera Therapeutics stock logo

Kymera Therapeutics NASDAQ:KYMR

$86.26 +3.55 (+4.29%)
Closing price 04:00 PM Eastern
Extended Trading
$86.24 -0.02 (-0.02%)
As of 05:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.